Insider transaction details
Edwards Lifesciences Corp Chief Financial Officer Scott B. Ullem disclosed a sale of 13,000 shares of company stock on April 9, 2026, in a Form 4 filing submitted to the Securities and Exchange Commission. The total proceeds from the sale were $1,040,544.
The filing specifies that 4,676 of those shares were sold at prices ranging from $80.225 to $80.750, while the remaining 8,324 shares exchanged hands at prices between $79.210 and $80.200.
Concurrent option exercise
The same Form 4 shows that, on April 9, 2026, Ullem exercised options to acquire 13,000 shares of Edwards Lifesciences common stock at an exercise price of $59.2567 per share, representing a total cash outlay of $770,337.
Following the sale and the exercise, Ullem's direct ownership stands at 39,699 shares. He also maintains an indirect stake of 266,318 shares through a trust, as reported in the filing.
Company valuation and analyst context
The insider activity arrives while Edwards Lifesciences is trading at a price-to-earnings ratio of 44 and carries a market capitalization of $45.6 billion. According to InvestingPro analysis referenced in the filing, the stock is trading below its Fair Value, suggesting it appears undervalued at current levels. The analysis also notes that 21 analysts recently revised earnings estimates upward for the pending period.
Recent operating and clinical updates
Edwards Lifesciences reported fourth-quarter 2025 adjusted earnings per share of $0.58, below analysts' expectations of $0.62. Revenue for the quarter was $1.57 billion, ahead of the $1.55 billion forecast and representing an 11.6% year-over-year increase.
In coverage moves, Stifel reiterated a Buy rating on Edwards Lifesciences, maintaining a price target of $110.00.
On the clinical front, the company disclosed two-year results from its TRISCEND II trial for the EVOQUE transcatheter tricuspid valve replacement system. The trial data showed lower all-cause mortality for treated patients and improvements in health status and quality of life, with no additional device-related risk reported.
Edwards Lifesciences also reiterated its Every Heartbeat Matters ambition to expand access to structural heart treatment, aiming to help 2 million more patients by 2030. The initiative has previously reached over 4 million underserved patients globally since 2014.
Documentation
The transactions were disclosed on a Form 4 filed with the Securities and Exchange Commission.